#USA #Boston #AI Technology #Outcomes4Me #Mika Health

Outcomes4Me Enhances Cancer Care with Mika Health Acquisition

In a significant move to bolster its patient care offerings, Outcomes4Me Inc. proudly announces the acquisition of the Mika Health app. This acquisition aims to significantly enhance their AI-driven platform dedicated to transforming cancer care. The partnership, finalized between Outcomes4Me Germany GmbH and Berlin-based Fosanis GmbH, signifies more than just a business merger; it embodies a shared mission of enhancing patient empowerment and support in their cancer journeys.

Impact on Cancer Patients

The Mika app has already demonstrated effectiveness, having engaged over 100,000 cancer patients around the globe. This app is not merely a tool but a clinically validated medical device designed specifically to address both the physical and psychological challenges faced by cancer patients. With proven strategies tailored to manage symptoms like anxiety, depression, and fatigue, Mika’s approach complements Outcomes4Me's offerings perfectly, enhancing the overall patient experience in cancer care.

Strategic Growth and Funding

Outcomes4Me has recently completed a successful funding round, raising $21 million. This financial boost underlines the company’s intention to grow its community of patients, as well as expand its commercial initiatives across international markets. The addition of the Mika Health app strengthens their product suite with innovative interventions capable of offering real-time symptom management and behavioral coaching, setting a precedent for digital oncology support globally.

Maya R. Said, Sc.D., the visionary Founder and CEO of Outcomes4Me, passionately remarked, "With this acquisition, we’re taking a significant step towards our mission to make cancer understandable and manageable for every patient wherever and whomever they are." The integration of Mika’s AI-based emotional support systems not only enhances the company’s functionality but also allows for further reach within European markets, leveraging Mika’s existing MDR IIa certification as a medical device.

Partnership Synergies

The synergy between Outcomes4Me and Mika Health is rooted in a mutual dedication to providing transparent, trustworthy, and empowering experiences for patients. Gandolf Finke, Ph.D., Founder and Managing Director of Fosanis GmbH, expressed enthusiasm about the merger, stating, "We’re excited to integrate our technology with a partner that shares our values of transparency, trust, and patient empowerment." This collaboration is expected to facilitate immediate benefits for users of the Mika app, ensuring seamless service continuity for existing patients.

Looking Ahead

Mark your calendars! Outcomes4Me will showcase its innovations at the upcoming HLTH Europe event in Amsterdam from June 16-19, 2025, where both the Outcomes4Me and Mika platforms will be highlighted in the AI Spotlight pavilion. Their booth, #F70-2, will be the place for attendees to discover how this partnership is redefining patient empowerment in cancer care.

About Outcomes4Me

Founded on the principles of patient empowerment, Outcomes4Me stands as a pioneering platform in the application of AI technologies for cancer care. They prioritize equipping patients with the tools they need to take charge of their health from diagnosis through treatment and beyond. The platform effectively integrates clinical guidelines, genomic data, and symptom tracking to provide personalized support tailored to individual patient needs.

About Mika Health

Mika Health offers a digital therapeutic platform that focuses on supporting cancer patients through artificial intelligence and scientifically validated methodologies. By continuously monitoring patient symptoms and providing personalized therapeutic resources, Mika enhances patients' quality of life during their treatment journey. This acquisition will allow the two companies to harness innovative technologies for optimized care experiences, marking a transformative era in digital health solutions for cancer treatment.